Similar Search Results

A Probability Approach to Pharmaceutical Demand and Price Setting: Does the Identity of the Third-Party Payer Mattersfor Prescribing Doctors?

Dalen, Dag Morten; Locatelli, Marilena; Sorisio, Enrico; … - CESifo - 2011

substitutes, but have had different and varying funding schemes - hospitals and the national insurance plan. A stochastic … national insurance. …

Persistent link: https://www.econbiz.de/10009371358

Choosing among Competing Blockbusters: Does the Identity of the Third-Party Payer Matter for Prescribing Doctors?

Dalen, Dag Morten; Sorisio, Enrico; Strøm, Steinar - CESifo - 2010

have had different and varying funding schemes - hospitals and the national insurance plan. We find that treatment choices … cost instead of a traditional fee-for-service insurance plan. When the doctors’ hospitals are covering the cost of this … treatment instead of insurance the total cost of treatment is significantly reduced. …

Persistent link: https://www.econbiz.de/10008727300

Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment

Brekke, Kurt R.; Holmås, Tor Helge; Straume, Odd Rune - CESifo - 2010

We study the impact of regulation on competition between brand-names and generics and pharmaceutical expenditures using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. First, we construct a vertical...

Persistent link: https://www.econbiz.de/10008799730

Margins and Market Shares: Pharmacy Incentives for Generic Substitution

Brekke, Kurt R.; Holmås, Tor Helge; Straume, Odd Rune - CESifo - 2012

generics and their market shares. This relationship is stronger for pharmaceuticals under reference pricing rather than …

Persistent link: https://www.econbiz.de/10010603857

Is Medicines Parallel Trade ‘Regulatory Arbitrage’?

Costa-i-Font, Joan - CESifo - 2015

In the European Union, medicines are regulated products subject to both single market (e.g., regional exhaustion of property rights) and country specific health care regulations (e.g., medicines pricing and distribution regulation). This gives rise to parallel trade (PT), a phenomenon that takes...

Persistent link: https://www.econbiz.de/10011274346

Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?

Brekke, Kurt R.; Grasdal, Astrid L.; Holmås, Tor Helge - CESifo - 2007

-patent pharmaceuticals, replacing the existing price cap (PC) regulation. We estimate the effect of the reform using a product level panel …

Persistent link: https://www.econbiz.de/10005406112

Direct to Consumer Advertising in Pharmaceutical Markets

Brekke, Kurt R.; Kuhn, Michael - CESifo - 2005

, firms are better off with a ban on DTCA. Finally, DTCA tends to lower welfare if insurance is generous (low copayments) and …

Persistent link: https://www.econbiz.de/10005406241

Reference Pricing of Pharmaceuticals

Brekke, Kurt R.; Königbauer, Ingrid; Straume, Odd Rune - CESifo - 2006

We consider a therapeutic market with potentially three pharmaceutical firms. Two of the firms offer horizontally differentiated brand-name drugs. One of the brand-name drugs is a new treatment under patent protection that will be introduced if the profits are sufficient to cover the entry...

Persistent link: https://www.econbiz.de/10005406396

Climate Policies: A Burden or a Gain?

Bréchet, Thierry; Tulkens, Henry - CESifo - 2013

That climate policies are costly is evident and therefore often creates major fears. But the alternative (no action) also has a cost. Mitigation costs and damages incurred depend on what the climate policies are; moreover, they are substitutes. This brings climate policies naturally in the realm...

Persistent link: https://www.econbiz.de/10010627557

Public Investment as Commitment

Gerlagh, Reyer; Liski, Matti - CESifo - 2011

Should public assets such as infrastructure, education, and the environment earn the same return as private investments? We consider if time-inconsistent decision-makers can gain from institutions that enforce cost-benefit rules on large projects that influence the economy as a whole. Long-term...

Persistent link: https://www.econbiz.de/10008833880